EU Pharma Reform, SPCs, Compulsory Licensing Among Parliament’s ‘Unfinished Business’

A number of legislative proposals will be coming under scrutiny at the newly constituted European Parliament in the coming months, including the pharma reform package and draft legislation on EU-level compulsory licensing and “unitary” supplementary protection certificates.

bundles bales of paper documents. stacks packs pile on the desk in the office
The European Parliament has identified 174 ongoing legislative dossiers • Source: Shutterstock

On 23 July, each of the new European Parliament’s 20 standing committees will hold a “constitutive” meeting during which they will elect a chair and up to four vice-chairs in preparation for the new legislative session.

They include the committee on the environment, public health and food safety (ENVI) and the legal affairs committee (JURI), which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug

 

The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.

Dutch HTA Calls For “Socially Acceptable” Price For Gene Editing Therapy Casgevy

 

Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.

GDPR Clarity For Pharma: Industry Code Nears EU-Wide Approval After Six-Year Journey

 
• By 

The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.

UK Initiative Steps Up Efforts To Tackle Recruitment Bottlenecks In Dementia Trials

 

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.

More from Geography

Malaysia Clarifies Drug Shortage Reporting Rules And Penalties For Non-Compliance

 

New guidance from the National Pharmaceutical Regulatory Agency responds to the medicines shortages crisis that Malaysia experienced a few years ago.

Dutch HTA Calls For “Socially Acceptable” Price For Gene Editing Therapy Casgevy

 

Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.

Aurobindo Expects US FTC Will Allow Lannett Acquisition

 
• By 

Aurobindo is confident its planned Lannett acquisition will meet US FTC standards after an attempt to acquire Sandoz assets was nixed in 2020. The deal also could widen Aurobindo’s US manufacturing presence.